FIT - Projects

8 projects

A randomized, two period, double-blind placebo-controlled and open label, multicenter extension study to determine the long-term safety and tolerbility of JNJ-54861911 in subjects in the early Alzheimer's Disease Spectrum

2015 - 2024

Ulrike Ernemann

Janssen-Cilag GmbH

A Multicenter, Follow-up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201

2016 - 2020

Ulrike Ernemann

Biogen Idec Research Limited

BMS CA209-498 – A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

2016 - 2019

Ulrike Ernemann

A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma

2015 - 2018

Ulrike Ernemann

Novartis Pharma AG

A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma

2015 - 2018

Ulrike Ernemann

Novartis Pharma AG

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

2015 - 2018

Ulrike Ernemann

AbbVie Deutschland GmbH & Co. KG

SIMPLIFY – A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis

2016

Till-Karsten Hauser

Biogen Idec Research Limited

PET-MR-Diagnostik – Prätherapeutische Diagnostik von semibenignen und semimalignen Gliomen mit simultaner PET/MR Diagnostik

2012 - 2015

Uwe Klose

Deutsche Forschungsgemeinschaft e.V. (DFG)

Help

will be deleted permanently. This cannot be undone.